Technical Articles

KRAS G13D & VCB结合试剂盒在靶向治疗中的应用
Application of KRAS G13D & VCB Binding Kit in Targeted Therapy
发布时间 2026-03-06
The KRAS gene is one of the most frequently mutated oncogenes in human cancers, appearing at high frequencies in pancreatic, colorectal, and lung cancers. As a central regulator of cellular signaling pathways, the KRAS protein functions like a molecular switch to control cell division and quiescence.
View details
  • Cancer
  • KRAS gene
  • KRAS G13D
  • Mutant oncogene
KRAS G12V & VCB结合试剂盒在靶向治疗中的应用
Application of KRAS G12V & VCB Binding Kit in Targeted Therapy
发布时间 2026-03-06
The KRAS gene is one of the most frequently mutated oncogenes in human malignancies, with this mutation detected in approximately one in seven cancers.
View details
  • Cancer
  • KRAS gene
  • KRAS G12V
  • Mutant oncogene
人KRAS G13D & VCB Binding 试剂盒在KRAS靶向治疗研究中的应用
Application of Human KRAS G13D & VCB Binding Kit in KRAS-Targeted Therapy Research
发布时间 2026-03-05
The KRAS gene is one of the most frequently mutated oncogenes in human cancers, occurring in approximately 10-25% of non-small cell lung cancer cases and is closely associated with poor prognosis.
View details
  • Cancer
  • KRAS G13D
  • Mutant oncogene
  • Non-small cell lung cancer
人KRAS G12D & SOS1 Binding 试剂盒在广谱KRAS靶向治疗研究中的应用
Application of Human KRAS G12D & SOS1 Binding Assay Kit in Broad-Spectrum KRAS-Targeted Therapy Research
发布时间 2026-03-04
The KRAS gene, as one of the most frequently mutated oncogenes in human cancers, has long been considered an "undruggable" target due to its protein structural characteristics.
View details
  • Drug Research
  • KRAS G12D & SOS1 Binding Kit (GDP load)
  • Mutant oncogene
  • Non-small cell lung cancer
KRAS G12C抑制剂耐药机制及应对策略研究进展
Research Progress on Resistance Mechanisms and Counterstrategies of KRAS G12C Inhibitors
发布时间 2026-03-02
The KRAS gene is one of the most frequently mutated oncogenes in cancer. Due to its protein structure lacking ideal drug-binding pockets and its extremely high affinity for GTP, KRAS mutations have long been considered an "undruggable" target.
View details
  • Cancer
  • KRAS G12C & CRBN Binding Kit (GDP loaded)
  • Mutant oncogene
  • Protein structure
Total 5
  • 1
Go to